COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
June 28, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
London, UK, June 28, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
June 23, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
Programme aims to support students from under-represented ethnic groups London, UK – 23 June 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to...
COMPASS Pathways plc to participate in JMP Securities and H.C. Wainwright investor conferences
June 08, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
LONDON, June 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
June 03, 2021 09:27 ET
|
COMPASS Pathfinder Ltd.
LONDON, June 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways plc announces financial results and business highlights for the first quarter 2021
May 13, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
Highlights: New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder Two...
COMPASS Pathways plc to announce first quarter 2021 financial results on 13 May 2021
May 06, 2021 08:00 ET
|
COMPASS Pathfinder Ltd.
London, UK, May 06, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways announces pricing of public offering
April 29, 2021 20:45 ET
|
COMPASS Pathfinder Ltd.
London, UK, 30 April 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based...
COMPASS Pathways launches proposed public offering
April 27, 2021 17:22 ET
|
COMPASS Pathfinder Ltd.
London, UK, April 27, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
April 15, 2021 03:00 ET
|
COMPASS Pathfinder Ltd.
London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...
COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
April 09, 2021 07:00 ET
|
COMPASS Pathfinder Ltd.
London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...